ClinicaliQ Trial Snapshot
- Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT07491718.
- What is being tested: Manganese-enhanced MRI imaging to investigate the physiological mechanisms of takotsubo cardiomyopathy (broken heart syndrome) and evaluate how different cardiac medications affect this condition.
- Patient eligibility overview: The trial recruits patients with diagnosed takotsubo cardiomyopathy, though specific inclusion/exclusion criteria would be detailed in the full protocol regarding age, comorbidities, and medication requirements.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The goal of this research study is to further understand the physiological mechanisms involved in a heart condition called takotsubo cardiomyopathy, also known as broken heart syndrome. Furthermore, the investigators will be assessing the effects different cardiac medications have on these physiological mechanisms. This will be achieved by performing cardiac MRI scans using a special dye called manganese. Manganese uptake in the heart is altered in patients with takotsubo cardiomyopathy. The investigators will study the effects that different cardiac medications have on manganese uptake.
Eligibility Snapshot
- : * Males and females >18 years of age * Clinical presentation of takotsubo cardiomyopathy * Have capacity to give formal consent
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.